Source: International Congress 2016 – IPF clinical
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Ivo A. Wiertz (Utrecht, Netherlands), Ivo Wiertz, Wim Wuyts, Coline van Moorsel, Renske Vorselaars, Miranda Ten Hoedt-Zijp, Wouter van Es, Matthijs van Oosterhout, Jan Grutters. Negative outcome of prednisone in possible idiopathic pulmonary fibrosis. Eur Respir J 2016; 48: Suppl. 60, 4571

Member's Comments

No comment yet.

Related content which might interest you: Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Non-pulmonary comorbidities in idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF treatment II Year: 2016 Assessment of nutritional status in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases Year: 2016 Does emphysema coexistence with IPF change prognosis? Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Aquoaporin-1 expression in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Subtypes of pulmonary emphysema on HRCT affect prognosis on combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Idiopathic pulmonary upper lobe fibrosis shows distinct features and poor prognosis compared to idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Role of midkine in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014 Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Validation of GAP score in Danish patients diagnosed with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 LATE-BREAKING ABSTRACT: Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases Year: 2015 Changes in the small airways in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013